Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genetic Analysis ASFRA:8V8 -3.24%39 PB Ratio is 1.44 as of Jul. 21, 2026, which is 13% above its 10-year median of 1.28. GuruFocus rates FRA:8V8 with a GF Score™ of 39/100 and a GF Value™ of €0.04. The stock has 4 warning signs investors should review. Among 195 Medical Diagnostics & Research companies, Genetic Analysis AS ranks worse than 51.28% on this metric.
Genetic Analysis AS stock PB Ratio (=2.03) is close to 1-year high of 2.25.
The historical rank and industry rank for Genetic Analysis AS's PB Ratio or its related term are showing as below:
FRA:8V8'
s PB Ratio Range Over the Past 10 Years
Min: 0.66 Med: 1.28 Max: 5.82
Current: 2.03
During the past 7 years, Genetic Analysis AS's highest PB Ratio was 5.82. The lowest was 0.66. And the median was 1.28.
FRA:8V8's PB Ratio is ranked worse than 51.28% of 195
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.96
vs FRA:8V8: 2.03
During the past 12 months, Genetic Analysis AS's average Book Value Per Share Growth Rate was -6.90% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -38.50% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -32.60% per year.
During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of Genetic Analysis AS was 9.60% per year. The lowest was -45.80% per year. And the median was -30.90% per year.
Back to Basics: PB Ratio
Genetic Analysis AS (FRA:8V8) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Genetic Analysis AS PB Ratio Related Terms
Genetic Analysis AS PB Ratio Historical Data
* Premium members only.
The historical data trend for Genetic Analysis AS's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Genetic Analysis AS's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genetic Analysis AS PB Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Genetic Analysis AS's PB Ratio distribution charts can be found below:
* The bar in red indicates where Genetic Analysis AS's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Genetic Analysis AS (FRA:8V8) has a PB Ratio of 1.44 as of Jul. 21, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Genetic Analysis AS and its competitors. This is 13% above median its historical median of 1.28. Over the past decade, Genetic Analysis AS's PB Ratio has ranged from 0.66 to 5.82. According to the industry distribution chart, Genetic Analysis AS ranks #100 out of 195 companies in the Medical Diagnostics & Research industry, placing it in the top 51.3%.
Is Genetic Analysis AS's PB Ratio too high?
Genetic Analysis AS's current PB Ratio of 1.44 is 13% above median its 10-year median of 1.28. Over the past 10 years, this metric has ranged from a low of 0.66 to a high of 5.82. The Medical Diagnostics & Research industry median PB Ratio is 1.96. Genetic Analysis AS's value of 1.44 is 26.5% below this industry median. Based on the distribution chart, Genetic Analysis AS ranks #100 out of 195 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Genetic Analysis AS has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Genetic Analysis AS's PB Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Genetic Analysis AS ranks #100 out of 195 companies for PB Ratio. This places Genetic Analysis AS in the lower half of its industry. The industry median PB Ratio is 1.96. Genetic Analysis AS's value of 1.44 is 26.5% below this benchmark. Historically, Genetic Analysis AS's own PB Ratio has ranged from 0.66 to 5.82 over the past decade. While the company's 10-year median is 1.28 vs. the industry median of 1.96, Genetic Analysis AS has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Diagnostics & Research company?
The median PB Ratio among Medical Diagnostics & Research companies is 1.96, based on 195 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genetic Analysis AS's current PB Ratio of 1.44 is 26.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Genetic Analysis AS and its competitors. For the Medical Diagnostics & Research industry, the median PB Ratio is 1.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genetic Analysis AS's current PB Ratio is 1.44, which is 13% above median its own 10-year median of 1.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genetic Analysis AS stock overvalued right now?
Genetic Analysis AS (FRA:8V8) has a current PB Ratio of 1.44. The stock's GF Value™ is €0.04, compared to a current price of €0.04 — trading 4.5% above its estimated fair value. The current PB Ratio is 1.44, which is 13% above median its 10-year median of 1.28 and 26.5% below the Medical Diagnostics & Research industry median of 1.96. Genetic Analysis AS's overall GF Score™ is 39/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Genetic Analysis AS (FRA:8V8), the current PB Ratio is 1.44 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genetic Analysis AS (FRA:8V8) Overvalued in 2026?
Based on GuruFocus' analysis, Genetic Analysis AS stock appears to be overvalued.
The current stock price of €0.04 is trading 4.5% above its estimated GF Value™ of €0.04.
Key valuation signals for FRA:8V8:
PB Ratio: 1.44 (13% above median its 10-year median of 1.28)
GF Value™: €0.04 vs. price of €0.04 (4.5% above fair value)
Industry Position: 26.5% below the Medical Diagnostics & Research median (#100 of 195)
No single metric tells the full story. See the FRA:8V8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genetic Analysis AS is a research-driven diagnostic company dedicated to delivering diagnostic solutions to the growing human microbiota market. It is providing a CE-marked gut microbiota analysis for testing bacterial imbalance in IBS and IBD patients. Geographically, it operates in the USA, Europe, and the Rest of the world. Geographically, the company sells products in the USA, Europe, and the rest of the world. The majority of its revenue is generated from the USA. The GA-map technology platform and product portfolio are currently used across three main market segments: Clinical diagnostics, research (academic and industry), and Consumer Health.
39GF Score
Get the complete analysis for FRA:8V8
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:8V8 has been successfully added to your 
